NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 14 December 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Martin Bradley Present for all items
3. Dr Matthew Bradley Present for all items
4. Paul Caulfield Items 1.1 to 4.2
5. Professor Sofia Dias Present for all items
6. Andrew Fox Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Present for all items
10. Dr Ivan Koychev Present for all items
11. Dr Guy Makin Present for all items
12. Dr Philip Mallender Present for all items
13. Professor David Meads Present for all items
14. Giles Monnickendam Present for all items
15. Dr Nathan Moore Present for all items
16. Malcolm Oswald Present for all items
17. Dr Paula Parvulescu Present for all items
18. Dr Rebecca Payne Present for all items
19. Carole Pitkeathley Present for all items
20. Dr Ben Searle Present for all items
21. Will Sullivan Present for all items
22. Dr Zenas Yiu Present for all items

NICE staff (key players) present

Helen Knight, Director of Medicines Evaluation Present for all items

Jacoline Bouvy, Programme Director Present for all items

Linda Landells, Associate Director Present for all items

Kate Moore, Project Manager Present for all items

Anna Willis, Heath Technology Assessment Adviser Present for all items

Nigel Gumbleton, Heath Technology Assessment Analyst Present for all items

External assessment group representatives present

Kate Ennis, BMJ Technology Assessment Group Items 1.1 to 4.2.2

Ben Farrar, BMJ Technology Assessment Group Items 1.1 to 4.2.2

Clinical, Patient & NHS England experts present

Professor Andrew Jones, Consultant Physician in Adult Cystic Fibrosis, Clinical expert – nominated by CF Trust and NHS England Items 1.1 to 4.2.2

Andrew Lilley, Pharmacy Clinical Services Lead and lead for respiratory – Clinical Expert, nominated by Neonatal and Paediatric Pharmacists Group Items 1.1 to 4.2.2

Dr Don Urquhart, Consultant in Paediatric Respiratory Medicine, Clinical Expert nominated by Scottish Medicines Consortium, Healthcare Improvement Scotland Items 1.1 to 4.2.2

Candice King, Involvement Manager at CF Trust – Patient Expert, nominated by CF Trust Items 1.1 to 4.2.2

Christina Walker, Organiser at CF Voices – Patient Expert, nominated by CF Voices

Yasmin Stammers, Senior Programme of Care manager, Internal Medicine, NHS Commissioning Expert, nominated by NHS England Items 1.1 to 4.2.2

Observers present

Ailsa Brown, Lead Health Economist, SMC Present for all items

Sharon Hems, Principal Pharmaceutical Analyst, SMC Present for all items

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Megan John, welcomed members of the committee and other attendees present to the meeting.
  2. The Chair noted apologies from Elliot Dash and Christopher Herring.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 16 November 2023

### Appraisal of Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

* 1. Part 1 – Open session
     1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Vertex Pharmaceuticals
     2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11187).
     3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by The Chair.
  2. Part 2 – Closed session (company representatives, patient and clinical experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11187>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Thursday 11 January 2024 and will start promptly at 09:00am.